Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Multiple Urolithin A clinical trials have reported improvements in inflammatory biomarkers as secondary or exploratory endpoints. While no trial has been specifically designed with inflammation as the primary outcome, the consistency of these findings across different populations and study designs has generated research interest in UA's anti-inflammatory potential. Chronic low-grade inflammation — sometimes called 'inflammaging' — is increasingly recognized as a key driver of age-related diseases including cardiovascular disease, neurodegeneration, and metabolic dysfunction. This page evaluates what the current evidence shows about Urolithin A's effects on inflammatory markers.
Before You Spend Another Dollar on Supplements, Read This
Most supplements can't cross the mitochondrial membrane. ReCellence was designed specifically to reach where energy is made.
Detailed Evidence
C-REACTIVE PROTEIN (CRP) — THE STRONGEST INFLAMMATORY SIGNAL C-reactive protein, a systemic marker of inflammation, has shown the most consistent reduction across UA trials. In the Liu 2022 JAMA Network Open trial (n=66, ages 65–90, 1000 mg/day for 4 months), plasma CRP decreased by approximately 30% in the UA group compared to placebo. This was a secondary endpoint but reached statistical significance. The Singh 2022 Cell Reports Medicine trial (n=88, ages 40–64) also measured CRP and reported reductions in both the 500 mg and 1000 mg dose groups over 4 months, though the magnitude varied by dose. CYTOKINE MARKERS: IL-6 AND TNF-α The Zhu 2024 Frontiers in Nutrition study in male athletes (1000 mg/day for 8 weeks) specifically measured exercise-induced inflammatory cytokines. The UA group showed reductions in interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) compared to placebo after resistance training sessions. These are acute inflammatory markers related to exercise recovery rather than chronic systemic inflammation. IMMUNE-RELATED INFLAMMATION The 2025 Nature Aging trial examining immune function in older adults also reported reductions in age-associated inflammatory markers as part of its immunosenescence evaluation. The study found improvements in immune cell populations that are associated with reduced chronic inflammation in aging. PROPOSED ANTI-INFLAMMATORY MECHANISM The anti-inflammatory effects of UA are thought to be downstream consequences of improved mitochondrial quality control. Damaged mitochondria can leak mitochondrial DNA and reactive oxygen species, which activate inflammatory pathways (particularly the NLRP3 inflammasome). By clearing damaged mitochondria through mitophagy, UA may reduce a key source of 'sterile inflammation' at the cellular level. PRECLINICAL ANTI-INFLAMMATORY DATA In preclinical models, UA has demonstrated anti-inflammatory effects in colitis models, neuroinflammation models, and metabolic inflammation models. These effects are consistent with the mitophagy-mediated mechanism but should not be directly extrapolated to human clinical benefits.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
The $3.2 Billion Mistake the Supplement Industry Doesn't Want You to Know
They sell you antioxidants. You need mitochondrial support. There's a massive difference — and your energy levels prove it.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Does Urolithin A reduce inflammation?
Multiple trials report reductions in CRP (~30% in JAMA trial), IL-6, and TNF-α. However, inflammation was a secondary endpoint in all trials. No trial was designed with inflammatory outcomes as the primary endpoint.
How much does Urolithin A reduce C-reactive protein?
CRP decreased approximately 30% vs placebo over 4 months in the JAMA trial (1000 mg/day). The Singh 2022 trial also reported CRP reductions in both 500 mg and 1000 mg groups, with magnitude varying by dose.
Does Urolithin A reduce IL-6 and TNF-α?
The Zhu 2024 athlete study showed reductions in IL-6 and TNF-α after resistance training sessions. These are acute exercise-induced inflammatory markers rather than chronic systemic inflammation. Sample size was limited.
What is inflammaging?
Inflammaging is chronic low-grade inflammation that develops with age. It is recognized as a key driver of age-related diseases including cardiovascular disease, neurodegeneration, and metabolic dysfunction.
How does Urolithin A reduce inflammation?
The proposed mechanism: UA-driven mitophagy clears damaged mitochondria that leak mtDNA and ROS, which activate the NLRP3 inflammasome. By reducing this source of "sterile inflammation," UA may reduce systemic inflammation.
Is CRP reduction with Urolithin A clinically meaningful?
The ~30% CRP reduction reached statistical significance, but whether it is clinically meaningful for individuals with already normal CRP levels is debated. CRP is a non-specific marker influenced by many factors.
Does Urolithin A help with exercise-induced inflammation?
The Zhu 2024 athlete study showed reductions in IL-6 and TNF-α after resistance training. This suggests UA may help with exercise recovery-related inflammation, though sample size was limited.
Can Urolithin A treat inflammatory diseases?
No. No trial has studied UA for inflammatory diseases (arthritis, colitis, etc.). Preclinical models show anti-inflammatory effects, but these should not be extrapolated to human clinical benefits. Consult a healthcare provider.
What inflammatory biomarkers were measured in UA trials?
C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). CRP showed the most consistent reduction. Cytokines were measured primarily in the athlete trial.
Is Urolithin A better than omega-3 for inflammation?
No head-to-head comparison has been conducted. Omega-3 has a larger evidence base for inflammation. UA targets mitochondrial dysfunction (upstream), while omega-3 directly modulates inflammatory pathways.
Does Urolithin A's anti-inflammatory effect persist long-term?
Unknown. Sustained CRP reduction was shown over 4 months. No trial measured inflammation after discontinuation. Long-term durability of anti-inflammatory effects is not characterized.
Were inflammation outcomes primary or secondary endpoints?
Secondary or exploratory in all published trials. No trial was designed with inflammatory outcomes as the primary endpoint. This is an important limitation for interpreting the anti-inflammatory evidence.
Does the immune function trial provide inflammation evidence?
Yes. The 2025 Nature Aging trial reported reductions in age-associated inflammatory markers as part of its immunosenescence evaluation, alongside improvements in immune cell populations.
What preclinical inflammation data exists for Urolithin A?
Preclinical models show anti-inflammatory effects in colitis, neuroinflammation, and metabolic inflammation models. These are consistent with the mitophagy-mediated mechanism but should not be directly extrapolated to humans.
Should I take Urolithin A for inflammation?
The anti-inflammatory evidence is secondary and moderate. No trial was designed for inflammatory outcomes. Decisions should be individualized with a healthcare provider. UA is not a treatment for inflammatory diseases.
Key Research Facts
C-reactive protein decreased approximately 30% in the UA group vs placebo over 4 months in the JAMA Network Open trial (n=66, ages 65–90).
Moderate EvidenceLiu et al., JAMA Network Open — doi:10.1001/jamanetworkopen.2021.44279
Both 500 mg and 1000 mg UA doses showed CRP reductions in the Singh 2022 trial (n=88), though magnitude varied by dose.
Moderate EvidenceSingh et al., Cell Reports Medicine — doi:10.1016/j.xcrm.2022.100633
Male athletes taking 1000 mg/day for 8 weeks showed reductions in IL-6 and TNF-α after resistance training sessions.
Emerging EvidenceZhu et al., Frontiers in Nutrition — PMC11536656
The proposed anti-inflammatory mechanism: UA-driven mitophagy reduces mitochondrial DAMPs that activate the NLRP3 inflammasome.
Moderate EvidenceD'Amico et al., Trends in Molecular Medicine — doi:10.1016/j.molmed.2021.04.009
A 2025 Nature Aging RCT reported reductions in age-associated inflammatory markers as part of immunosenescence evaluation.
Emerging EvidenceNature Aging — doi:10.1038/s43587-025-00996-x
Inflammation has been a secondary or exploratory endpoint in all published UA trials — no trial has been designed with inflammatory outcomes as the primary endpoint.
Strong EvidenceJayatunga et al., Ageing Research Reviews — pubmed:39002645
Chronic low-grade inflammation (inflammaging) is recognized as a key driver of cardiovascular disease, neurodegeneration, and metabolic dysfunction in aging.
Strong EvidenceLópez-Otín et al., Cell — doi:10.1016/j.cell.2022.11.001
In preclinical models, UA has demonstrated anti-inflammatory effects in colitis, neuroinflammation, and metabolic inflammation models.
Moderate EvidenceD'Amico et al., Trends in Molecular Medicine — doi:10.1016/j.molmed.2021.04.009
CRP reductions correlated with mitochondrial biomarker improvements, supporting a mechanistic link between mitophagy and reduced systemic inflammation.
Moderate EvidenceLiu et al., 2022 — doi:10.1001/jamanetworkopen.2021.44279
Head-to-head comparisons with established anti-inflammatory interventions (omega-3, exercise, NSAIDs) have not been conducted.
Strong EvidenceJayatunga et al., 2024 — pubmed:39002645
Citations & External Resources
ClinicalTrials.gov — Search: Urolithin A
FDA GRAS Notice GRN 000833 — Urolithin A
EFSA Novel Food Catalogue — Urolithin A
PubMed — Urolithin A research
Nature Medicine — Ryu et al. 2016 (Landmark Study)
JAMA Network Open — Liu et al. 2022 (Muscle Endurance RCT)
Frontiers in Nutrition — Zhu et al. 2024 (Athlete Inflammation Data)
Nature Aging — Immune/Inflammation Trial 2025
PubMed — Urolithin A inflammation research
Scientists Call It 'The Hallmark of Aging.' We Call It Fixable.
Mitochondrial dysfunction is now recognized as a primary driver of aging. Here's the cellular renewal protocol that targets it directly.
Related Reading
Urolithin A & Healthy Aging: Research Context
Urolithin A Benefits: Clinical Evidence
Urolithin A & Exercise Performance: Research Summary
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026